[Comparative double-blind study of Bi-Profenid and oxyphenbutazone in sports pathology].
Effectiveness and tolerance of ketoprofen in sustained-release tablets (Bi-Profenid 150 mg) were investigated in a double blind trial in 44 athletes who had recently sprained an ankle. Patients were given either 300 mg Bi-Profenid or 400 mg oxyphenbutazone daily for seven days. Treatment regimens were assigned at random. Results were assessed as excellent or good in 85% of patients given Bi-Profenid and 50% of those given oxyphenbutazone. Spontaneous pain resolved in 19 patients receiving Bi-Profenid and in 6 under oxyphenbutazone. Decrease in pain upon physical examination and in articular circumference was significantly greater with Bi-Profenid as compared with oxyphenbutazone. The chance of rapidly resuming sport was better with Bi-Profenid. Tolerance was excellent in 68.2% of patients with Bi-Profenid and 59% of those with oxyphenbutazone. This investigation thus emphasizes the value of Bi-Profenid in sport pathology.
D000293:Adolescent; D000328:Adult; D016512:Ankle Injuries; D001265:Athletic Injuries / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007660:Ketoprofen / Q000627:therapeutic use*; D008297:Male; D010113:Oxyphenbutazone / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy; D010666:Phenylpropionates / Q000627:therapeutic use*; D011897:Random Allocation; D013180:Sprains and Strains / Q000188:drug therapy
D010666:Phenylpropionates; D007660:Ketoprofen; D010113:Oxyphenbutazone
Etude comparative à double insu di Bi-Profénid et de l'oxyphenbutazone en pathologie du sport.